Interferon-β dose and efficacy: The OPTIMS study

Neurological Sciences

Volumn 22, Issue 2, 2001, Pages 201-203

  Durelli, L ^a   Oggero, A ^a   Verdun, E ^a   Barbero, P ^a   Pipieri, A ^a   Isoardo, G ^a   Ricci, A ^a   C lerirn, M ^a   Rrariar, C ^a   Rerpamasoo, R ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

High dose IFN treatment; Interferon beta; Multiple sclerosis; Non responders

Indexed keywords

BETA INTERFERON; INTERFERON BETA SERINE; PLACEBO;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE CALCULATION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REDUCTION; RELAPSE; SIDE EFFECT; TREATMENT FAILURE;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT FAILURE;

EID: 0034787356     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100720170024     Document Type: Conference Paper

References (10)

1. The IFNβ Multiple Sclerosis Study Group (1993) Interferon beta-1 h is effective in relapsing-remitting multiple sclerosis. 1. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
2. Khan OA, Hebel JR (1998) Incidence of exacerbations in the first 90 days of treated with recombinant human intcrferon beta-lb in patients with relapsing-remitting multiple sclerosis. Ann Neurol44:l38-139
3. Arnason B, Dianzani F (1998) Correlation of the appearance of anti-interfcron antibodies during treatment and diminution of efficacy: summary of an international workshop on antiinterferon antibodies. J Interferon Cytokine Res 18:639-644
4. Pctkau J, Wite R et al (1997) Neutralizing antibodies and the efficacy of the Interferon beta-lb in relapsing-remitting multiple sclerosis. Mult Scler 3:402 (abstract)
5. Knobler RL, Greenstein JI, Johnson KP et al (1993) Systemic recombinant human interferon-beta treatment of relapsingremitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res 13:333-340
6. Paly D, Li D. Oger J et al (1994) Magnetic resonance imaging in the evaluation of clinical trials in multiple sclerosis. Ann Neurol 47[Suppl]:865-866
7. The IFNβ Multiple Sclerosis Study Group and the University of British Columbia MS/MRI analysis group (1995) Interferon beta-lb in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277-1285
8. The PRISMS Study Group (1998) Randomized, double-blind placebo-controlled study of interferon beta-1 a in relapsingremitting multiple sclerosis: clinical results. Lancet 352:1498-1504
9. The Once Weekly Interferon for MS Study Group (OWIMS) (1999) Evidence of interferon beta-la dose response in relapsing-remitting MS. The OWIMS study. Neurology 53:679-686
10. McFarland HF, Frank JA, Abcrt PS et al (1992) Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 32:758-766